Risk factor for development of cervicouterine cancer associated to HVP: p53 codon 72 polimorphism in women attending hospital, care;Factores de riesgo para cáncer cervicouterino por IVPH: Polimorfismo del codón 72 del gen oncosupresor p53 en mujeres que acuden a atención hospitalaria

Ginecologia y Obstetricia de Mexico

Volumn 71, Issue JAN., 2003, Pages 12-15

  Álvarez, A Sifuentes ^a   Reyes Romero, Miguel ^a  

^a UNIVERSIDAD JUÁREZ DEL ESTADO DE DURANGO   (Mexico)

Author keywords

Cervicouterine cancer; Human papiloma virus; p53

Indexed keywords

ARGININE; GENOMIC DNA; PROLINE; PROTEIN P53;

ALLELE; ARTICLE; CODON; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENOTYPE; HOMOZYGOTE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WART VIRUS;

CERVIX UTERI; CODON; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0037274730     PISSN: 03009041     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. IARC/WHO Monographs on the evaluation of carcinogenic risks to humans. International Agency for Research on Cancer. 1995; 64.
2. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-34.
3. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M. Complete switch from Mdm2 to human papilloma-virus E6-mediated degradation of p53 in cervical cancer cells. Proc Nat Acad Sci USA. 2001; 98: 1218-23.
4. Zehbe I, Voglino G, Willander E, Delius H, Marongiu A, Edler L, Klimek F, Andersson S, Tommasino M. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 2001; 61: 608-11.
5. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L. Is p53 plymorphism mintained by natural selection? Hum Hered 1994; 44: 266-70.
6. Van Duin M, Snijders PJF, Vossen MTM, Klaassen E, Voohorst F, Verheijen RHM, Helmerhorst TJ, Meijer C, Walboomers JMM. Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 2000; 81: 317-25.
7. Agorastos T, Lambropoulos AF, Constantinidis TC, Kotsis A, Bontis JN. p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. Eur J Cancer Prev. 2000; 9: 113-8.
8. Madeleine MM, Shera K, Schuwartz SM, Daling JR, Galloway DA, Wipf GC, Carter JJ, McKnight B, McDougall JK. The p53 Arg-72pro polimorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers Prev. 2000; 9: 225-7.
9. Baek WK, Cho JW, Suh SI, Suh MH, Shin DH, Cho CH, Lee TS, Cha SD. p53 codon 72 polymorphism and risk of cervical carcinoma in korean women. J Korean Med Sci 2000; 15: 65-7.
10. Tenti P, Vesentini N, Rondo Spaudo M, Zappatore R, Migliora P, Carnevali L, Ranzani GN. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from Northern Italy. Cancer Epidemiol Biomarkers Prev 2000; 9: 435-8.
11. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998; 352: 1631.
12. Makni H, Franco EL, Kaiano J, Villa LL, Labrecque S, Dudley R, Storey A, Matlashewski G. p53 polymorphism in codon 72 and risk of human papillomavirus-induce cervical cancer: effect of inter-laboratory variation. Int J Cancer. 2000; 87: 528-33.